|
1
|
Blackburn EH: Structure and function of
telomeres. Nature. 350:569–573. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hackett JA, Feldser DM and Greider CW:
Telomere dysfunction increases mutation rate and genomic
instability. Cell. 106:275–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rudolph KL, Millard M, Bosenberg MW and
DePinho RA: Telomere dysfunction and evolution of intestinal
carcinoma in mice and humans. Nat Genet. 28:155–159. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levy MZ, Allsopp RC, Futcher AB, Greider
CW and Harley CB: Telomere end-replication problem and cell aging.
J Mol Biol. 225:951–960. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harley CB, Futcher AB and Greider CW:
Telomeres shorten during ageing of human fibroblasts. Nature.
345:458–460. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
von Figura G, Hartmann D, Song Z and
Rudolph KL: Role of telomere dysfunction in aging and its detection
by biomarkers. J Mol Med. 87:1165–1171. 2009.PubMed/NCBI
|
|
7
|
Cosme-Blanco W, Shen MF, Lazar AJ, et al:
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo
by initiating p53-dependent cellular senescence. EMBO Rep.
8:497–503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thanasoula M, Escandell JM, Martinez P, et
al: p53 prevents entry into mitosis with uncapped telomeres. Curr
Biol. 20:521–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brassat U, Balabanov S, Bali D, et al:
Functional p53 is required for effective execution of telomerase
inhibition in BCR-ABL-positive CML cells. Exp Hematol. 39:66–76.
e1–2. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Artandi SE and DePinho RA: Telomeres and
telomerase in cancer. Carcinogenesis. 31:9–18. 2009. View Article : Google Scholar
|
|
11
|
Petitjean A, Mathe E, Kato S, et al:
Impact of mutant p53 functional properties on TP53 mutation
patterns and tumor phenotype: lessons from recent developments in
the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lasko D, Cavenee W and Nordenskjold M:
Loss of constitutional heterozygosity in human cancer. Annu Rev
Genet. 25:281–314. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goh AM, Coffill CR and Lane DP: The role
of mutant p53 in human cancer. J Pathol. 223:116–126. 2011.
View Article : Google Scholar
|
|
14
|
Whibley C, Pharoah PD and Hollstein M: p53
polymorphisms: cancer implications. Nat Rev Cancer. 9:95–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Knudson AG Jr: Mutation and cancer:
statistical study of retinoblastoma. Proc Natl Acad Sci USA.
68:820–823. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saeki H, Kitao H, Yoshinaga K, et al:
Copy-neutral loss of heterozygosity at the p53 locus in
carcinogenesis of esophageal squamous cell carcinomas associated
with p53 mutations. Clin Cancer Res. 17:1731–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cawthon RM: Telomere measurement by
quantitative PCR. Nucleic Acids Res. 30:e472002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gil ME and Coetzer TL: Real-time
quantitative PCR of telomere length. Mol Biotechnol. 27:169–172.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Babizhayev MA, Savel'yeva EL, Moskvina SN
and Yegorov YE: Telomere length is a biomarker of cumulative
oxidative stress, biologic age, and an independent predictor of
survival and therapeutic treatment requirement associated with
smoking behavior. Am J Ther. 18:e209–226. 2011. View Article : Google Scholar
|
|
20
|
Baird DM: Telomere dynamics in human
cells. Biochimie. 90:116–121. 2008. View Article : Google Scholar
|
|
21
|
von Zglinicki T: Oxidative stress shortens
telomeres. Trends Biochem Sci. 27:339–344. 2002.PubMed/NCBI
|
|
22
|
Epel ES, Blackburn EH, Lin J, et al:
Accelerated telomere shortening in response to life stress. Proc
Natl Acad Sci USA. 101:17312–17315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Artandi SE, Chang S, Lee SL, et al:
Telomere dysfunction promotes non-reciprocal translocations and
epithelial cancers in mice. Nature. 406:641–645. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murnane JP: Telomeres and chromosome
instability. DNA Repair. 5:1082–1092. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen M, Ye Y, Yang H, et al: Genome-wide
profiling of chromosomal alterations in renal cell carcinoma using
high-density single nucleotide polymorphism arrays. Int J Cancer.
125:2342–2348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
27
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tabori U, Nanda S, Druker H, Lees J and
Malkin D: Younger age of cancer initiation is associated with
shorter telomere length in Li-Fraumeni syndrome. Cancer Res.
67:1415–1418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trkova M, Prochazkova K, Krutilkova V,
Sumerauer D and Sedlacek Z: Telomere length in peripheral blood
cells of germline TP53 mutation carriers is shorter than that of
normal individuals of corresponding age. Cancer. 110:694–702. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Radpour R, Barekati Z, Haghighi MM, et al:
Correlation of telomere length shortening with promoter methylation
profile of p16/Rb and p53/p21 pathways in breast cancer. Mod
Pathol. 23:763–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pooley KA, Sandhu MS, Tyrer J, et al:
Telomere length in prospective and retrospective cancer
case-control studies. Cancer Res. 70:3170–3176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gramatges MM, Telli ML, Balise R and Ford
JM: Longer relative telomere length in blood from women with
sporadic and familial breast cancer compared with healthy controls.
Cancer Epidemiol Biomarkers Prev. 19:605–613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng YL, Ambrosone C, Byrne C, Davis W,
Nesline M and McCann SE: Telomere length in blood cells and breast
cancer risk: investigations in two case-control studies. Breast
Cancer Res Treat. 120:769–775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Svenson U, Nordfjall K, Stegmayr B, et al:
Breast cancer survival is associated with telomere length in
peripheral blood cells. Cancer Res. 68:3618–3623. 2008. View Article : Google Scholar : PubMed/NCBI
|
